The Molecular Logic Behind Roche’s Colon Cancer Priority Review That No One Is Explaining
Roche's FDA Priority Review for Tecentriq in dMMR/MSI-H stage III colon cancer has an October 9 decision date. Here's...
Roche
FDA’s Priority Review Acceptance for Giredestrant NDA Sets a November 2026 Decision Clock for the Adjuvant SERD Market
FDA accepted Roche's giredestrant NDA under Priority Review on June 2, 2026—targeting a November 2026 action date for the...
Roche’s Giredestrant ASCO Play Is a Signal to Every Endocrine Therapy Competitor
Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...